Since the 2018 Farm Bill legalized the cultivation and sale of industrial hemp and its extracts, the CBD industry has been steadily growing. Effective against a wide range of ailments and most importantly, devoid of cannabis’ infamous high, cannabidiol has quickly become the go-to ingredient for people who have lost faith in pharmaceuticals. However, the industry is barely regulated, and the U.S. Food and Drug Administration (“FDA”) has repeatedly called for stakeholders to provide reliable scientific data, especially on the effects of long term use on the liver.
A group of CBD brands is doing just that. They have sponsored a study to determine any potential liver toxicity and the safety of CBD, and the study will be carried out by Colorado-based clinical research company ValidCare. Slated to commence this July, the clinical study, which was designed with heavy input from a branch of the FDA, is being interpreted as a critical step
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.